Skip to main content
Erschienen in: Forensic Toxicology 2/2015

01.07.2015 | Original Article

Identification of AB-FUBINACA metabolites in human hepatocytes and urine using high-resolution mass spectrometry

verfasst von: Marisol S. Castaneto, Ariane Wohlfarth, Shaokun Pang, Mingshe Zhu, Karl B. Scheidweiler, Robert Kronstrand, Marilyn A. Huestis

Erschienen in: Forensic Toxicology | Ausgabe 2/2015

Einloggen, um Zugang zu erhalten

Abstract

AB-FUBINACA, N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide, is an indazole synthetic cannabinoid identified in drug seizures around the world. Few metabolism data are available, despite the need for human urinary markers to detect AB-FUBINACA intake. Our main objective was to identify suitable analytical targets by analyzing human hepatocyte incubation samples with high-resolution mass spectrometry (HRMS) and to confirm the results in authentic urine specimens. We also determined AB-FUBINACA’s metabolic stability in human liver microsomes (HLMs) and compared hepatocyte and urine results with in silico predictions. The metabolic stability of AB-FUBINACA was determined in pooled HLMs (1 µmol/l, up to 1 h). The metabolite profile of human hepatocytes (10 µmol/l, 1 and 3 h) and urine samples from two subjects were determined by HRMS using information-dependent tandem-mass spectrometry (MS-MS) acquisition. Data were analyzed with MetabolitePilot™ software utilizing different processing algorithms, including generic peak finding, mass defect filtering, neutral loss, and product ion filtering. In silico metabolite prediction was performed with MetaSite™ software. AB-FUBINACA’s half-life in HLMs was 62.6 ± 4.0 min. AB-FUBINACA produced 11 metabolites (2 glucuronides) in human hepatocytes and 10 were identified in authentic human urine. Major metabolic pathways were terminal amide hydrolysis, acyl glucuronidation and hydroxylation at the aminooxobutane moiety. Epoxidation followed by hydrolysis, hydroxylation at the indazole moiety and dehydrogenation were minor pathways. Defluorination did not occur. Seventeen first-generation metabolites were predicted in silico, of which seven were observed in vitro and eight in vivo. We recommend AB-FUBINACA carboxylic acid, hydroxy AB-FUBINACA carboxylic acid, dihydrodiol AB-FUBINACA and dihydrodiol AB-FUBINACA carboxylic acid as suitable urinary markers.
Literatur
1.
Zurück zum Zitat Castaneto MS, Gorelick DA, Desrosiers NA, Hartman RL, Pirard S, Huestis MA (2014) Synthetic cannabinoids: epidemiology, pharmacodynamics, and clinical implications. Drug Alcohol Depend 144:12–41PubMedCrossRef Castaneto MS, Gorelick DA, Desrosiers NA, Hartman RL, Pirard S, Huestis MA (2014) Synthetic cannabinoids: epidemiology, pharmacodynamics, and clinical implications. Drug Alcohol Depend 144:12–41PubMedCrossRef
3.
Zurück zum Zitat US Drug Enforcement Administration (2013) Establishment of drug codes for 26 substances. Final rule. Fed Regist 78:664–666 US Drug Enforcement Administration (2013) Establishment of drug codes for 26 substances. Final rule. Fed Regist 78:664–666
4.
Zurück zum Zitat Buchler JP, Hayes MJ, Hegde SG, Hockerman SL, Jones DE, Kortum SW, Rico JG, Tenbrink RE, Wu KK (2009) Indazole derivatives. US Patent CA 2714573 A1:1–283 Buchler JP, Hayes MJ, Hegde SG, Hockerman SL, Jones DE, Kortum SW, Rico JG, Tenbrink RE, Wu KK (2009) Indazole derivatives. US Patent CA 2714573 A1:1–283
5.
Zurück zum Zitat Brents LK, Reichard EE, Zimmerman SM, Moran JH, Fantegrossi WE, Prather PL (2011) Phase I hydroxylated metabolites of the K2 synthetic cannabinoid JWH -018 retain in vitro and in vivo cannabinoid 1 receptor affinity and activity. PLoS One 6:e21917PubMedCentralPubMedCrossRef Brents LK, Reichard EE, Zimmerman SM, Moran JH, Fantegrossi WE, Prather PL (2011) Phase I hydroxylated metabolites of the K2 synthetic cannabinoid JWH -018 retain in vitro and in vivo cannabinoid 1 receptor affinity and activity. PLoS One 6:e21917PubMedCentralPubMedCrossRef
6.
Zurück zum Zitat Uchiyama N, Matsuda S, Wakana D, Kikura-Hanajiri R, Goda Y (2013) New cannabimimetic indazole derivatives, N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide (AB-PINACA) and N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-caboxamide (AB-FUBINACA) identified as designer drugs in illegal products. Forensic Toxicol 31:93–100CrossRef Uchiyama N, Matsuda S, Wakana D, Kikura-Hanajiri R, Goda Y (2013) New cannabimimetic indazole derivatives, N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide (AB-PINACA) and N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-caboxamide (AB-FUBINACA) identified as designer drugs in illegal products. Forensic Toxicol 31:93–100CrossRef
8.
Zurück zum Zitat Drug Enforcement Administration (2014) Schedules of controlled substances: temporary placement of four synthetic cannabinoids into schedule I: notice of intent. Fed Regist 79:7577–7582 Drug Enforcement Administration (2014) Schedules of controlled substances: temporary placement of four synthetic cannabinoids into schedule I: notice of intent. Fed Regist 79:7577–7582
9.
Zurück zum Zitat Centers for Disease Control and Prevention (2013) Notes from the field: severe illness associated with synthetic cannabinoid use—Brunswick, Georgia, 2013. MMWR Morb Mortal Wkly Rep 62:939 Centers for Disease Control and Prevention (2013) Notes from the field: severe illness associated with synthetic cannabinoid use—Brunswick, Georgia, 2013. MMWR Morb Mortal Wkly Rep 62:939
11.
Zurück zum Zitat Gurney SMR, Scott KS, Kacinko SL, Presley BC, Logan BK (2014) Pharmacology, toxicology, and adverse effects of synthetic cannabinoid drugs. Forensic Sci Rev 26:53–78 Gurney SMR, Scott KS, Kacinko SL, Presley BC, Logan BK (2014) Pharmacology, toxicology, and adverse effects of synthetic cannabinoid drugs. Forensic Sci Rev 26:53–78
13.
Zurück zum Zitat De Brabanter N, Esposito S, Tudela E, Lootens L, Meuleman P, Leroux-Roels G, Deventer K, Van Eenoo P (2013) In vivo and in vitro metabolism of the synthetic cannabinoid JWH-200. Rapid Commun Mass Spectrom 27:2115–2126PubMedCrossRef De Brabanter N, Esposito S, Tudela E, Lootens L, Meuleman P, Leroux-Roels G, Deventer K, Van Eenoo P (2013) In vivo and in vitro metabolism of the synthetic cannabinoid JWH-200. Rapid Commun Mass Spectrom 27:2115–2126PubMedCrossRef
14.
Zurück zum Zitat Grigoryev A, Melnik A, Savchuk S, Simonov A, Rozhanets V (2011) Gas and liquid chromatography-mass spectrometry studies on the metabolism of the synthetic phenylacetylindole cannabimimetic JWH-250, the psychoactive component of smoking mixtures. J Chromatogr B 879:2519–2526CrossRef Grigoryev A, Melnik A, Savchuk S, Simonov A, Rozhanets V (2011) Gas and liquid chromatography-mass spectrometry studies on the metabolism of the synthetic phenylacetylindole cannabimimetic JWH-250, the psychoactive component of smoking mixtures. J Chromatogr B 879:2519–2526CrossRef
15.
Zurück zum Zitat Wintermeyer A, Moller I, Thevis M, Jubner M, Beike J, Rothschild MA, Bender K (2010) In vitro phase I metabolism of the synthetic cannabimimetic JWH-018. Anal Bioanal Chem 398:2141–2153PubMedCrossRef Wintermeyer A, Moller I, Thevis M, Jubner M, Beike J, Rothschild MA, Bender K (2010) In vitro phase I metabolism of the synthetic cannabimimetic JWH-018. Anal Bioanal Chem 398:2141–2153PubMedCrossRef
16.
Zurück zum Zitat Takayama T, Suzuki M, Todoroki K, Inoue K, Min JZ, Kikura-Hanajiri R, Goda Y, Toyo’oka T (2014) UPLC/ESI-MS/MS-based determination of metabolism of several new illicit drugs, ADB-FUBINACA, AB-FUBINACA, AB-PINACA, QUPIC, 5F-QUPIC and alpha-PVT, by human liver microsomes. Biomed Chromatogr 28:831–838PubMedCrossRef Takayama T, Suzuki M, Todoroki K, Inoue K, Min JZ, Kikura-Hanajiri R, Goda Y, Toyo’oka T (2014) UPLC/ESI-MS/MS-based determination of metabolism of several new illicit drugs, ADB-FUBINACA, AB-FUBINACA, AB-PINACA, QUPIC, 5F-QUPIC and alpha-PVT, by human liver microsomes. Biomed Chromatogr 28:831–838PubMedCrossRef
17.
Zurück zum Zitat Jang M, Shin I, Yang W, Chang H, Yoo HH, Lee J, Kim E (2014) Determination of major metabolites of MAM-2201 and JWH-122 in in vitro and in vivo studies to distinguish their intake. Forensic Sci Int 244:85–91PubMedCrossRef Jang M, Shin I, Yang W, Chang H, Yoo HH, Lee J, Kim E (2014) Determination of major metabolites of MAM-2201 and JWH-122 in in vitro and in vivo studies to distinguish their intake. Forensic Sci Int 244:85–91PubMedCrossRef
18.
Zurück zum Zitat Holm NB, Pedersen AJ, Dalsgaard PW, Linnet K (2015) Metabolites of 5F-AKB-48, a synthetic cannabinoid receptor agonist, identified in human urine and liver microsomal preparations using liquid chromatography high-resolution mass spectrometry. Drug Test Anal 7:199–206PubMedCrossRef Holm NB, Pedersen AJ, Dalsgaard PW, Linnet K (2015) Metabolites of 5F-AKB-48, a synthetic cannabinoid receptor agonist, identified in human urine and liver microsomal preparations using liquid chromatography high-resolution mass spectrometry. Drug Test Anal 7:199–206PubMedCrossRef
19.
Zurück zum Zitat Jin MJ, Lee J, In MK, Yoo HH (2013) Characterization of in vitro metabolites of CP 47,497, a synthetic cannabinoid, in human liver microsomes by LC–MS/MS. J Forensic Sci 58:195–199PubMedCrossRef Jin MJ, Lee J, In MK, Yoo HH (2013) Characterization of in vitro metabolites of CP 47,497, a synthetic cannabinoid, in human liver microsomes by LC–MS/MS. J Forensic Sci 58:195–199PubMedCrossRef
20.
Zurück zum Zitat Gandhi AS, Wohlfarth AW, Zhu M, Pang S, Castaneto M, Scheidweiler KB, Huestis MA (2015) High-resolution mass spectrometric metabolite profiling of a novel synthetic designer drug, N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide (STS-135), using cryopreserved human hepatocytes and assessment of metabolic stability with human liver microsomes. Drug Test Anal 7:187–198PubMedCrossRef Gandhi AS, Wohlfarth AW, Zhu M, Pang S, Castaneto M, Scheidweiler KB, Huestis MA (2015) High-resolution mass spectrometric metabolite profiling of a novel synthetic designer drug, N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide (STS-135), using cryopreserved human hepatocytes and assessment of metabolic stability with human liver microsomes. Drug Test Anal 7:187–198PubMedCrossRef
21.
Zurück zum Zitat Gandhi AS, Zhu M, Pang S, Wohlfarth A, Scheidweiler KB, Liu HF, Huestis MA (2013) First characterization of AKB-48 metabolism, a novel synthetic cannabinoid, using human hepatocytes and high-resolution mass spectrometry. AAPS J 15:1091–1098PubMedCentralPubMedCrossRef Gandhi AS, Zhu M, Pang S, Wohlfarth A, Scheidweiler KB, Liu HF, Huestis MA (2013) First characterization of AKB-48 metabolism, a novel synthetic cannabinoid, using human hepatocytes and high-resolution mass spectrometry. AAPS J 15:1091–1098PubMedCentralPubMedCrossRef
22.
Zurück zum Zitat Wohlfarth A, Gandhi AS, Pang S, Zhu M, Scheidweiler KB, Huestis MA (2014) Metabolism of synthetic cannabinoids PB-22 and its 5-fluoro analog, 5F-PB-22, by human hepatocyte incubation and high-resolution mass spectrometry. Anal Bioanal Chem 406:1763–1780PubMedCrossRef Wohlfarth A, Gandhi AS, Pang S, Zhu M, Scheidweiler KB, Huestis MA (2014) Metabolism of synthetic cannabinoids PB-22 and its 5-fluoro analog, 5F-PB-22, by human hepatocyte incubation and high-resolution mass spectrometry. Anal Bioanal Chem 406:1763–1780PubMedCrossRef
23.
Zurück zum Zitat Wohlfarth A, Pang S, Zhu M, Gandhi AS, Scheidweiler KB, Huestis MA (2014) Metabolism of RCS-8, a synthetic cannabinoid with cyclohexyl structure, in human hepatocytes by high-resolution MS. Bioanalysis 6:1187–2000PubMedCentralPubMedCrossRef Wohlfarth A, Pang S, Zhu M, Gandhi AS, Scheidweiler KB, Huestis MA (2014) Metabolism of RCS-8, a synthetic cannabinoid with cyclohexyl structure, in human hepatocytes by high-resolution MS. Bioanalysis 6:1187–2000PubMedCentralPubMedCrossRef
24.
Zurück zum Zitat Wohlfarth A, Pang S, Zhu M, Gandhi AS, Scheidweiler KB, Liu HF, Huestis MA (2013) First metabolic profile of XLR-11, a novel synthetic cannabinoid, obtained by using human hepatocytes and high-resolution mass spectrometry. Clin Chem 59:1638–1648PubMedCrossRef Wohlfarth A, Pang S, Zhu M, Gandhi AS, Scheidweiler KB, Liu HF, Huestis MA (2013) First metabolic profile of XLR-11, a novel synthetic cannabinoid, obtained by using human hepatocytes and high-resolution mass spectrometry. Clin Chem 59:1638–1648PubMedCrossRef
25.
Zurück zum Zitat Strano-Rossi S, Anzilotti L, Dragoni S, Pellegrino RM, Goracci L, Pascali VL, Cruciani G (2014) Metabolism of JWH-015, JWH-098, JWH-251, and JWH-307 in silico and in vitro: a pilot study for the detection of unknown synthetic cannabinoids metabolites. Anal Bioanal Chem 406:3621–3636PubMedCrossRef Strano-Rossi S, Anzilotti L, Dragoni S, Pellegrino RM, Goracci L, Pascali VL, Cruciani G (2014) Metabolism of JWH-015, JWH-098, JWH-251, and JWH-307 in silico and in vitro: a pilot study for the detection of unknown synthetic cannabinoids metabolites. Anal Bioanal Chem 406:3621–3636PubMedCrossRef
26.
Zurück zum Zitat Thomsen R, Nielsen LM, Holm NB, Rasmussen HB, Linnet K (2014) Synthetic cannabimimetic agents metabolized by carboxylesterases. Drug Test Anal. doi:10.1002/dta.1731 PubMed Thomsen R, Nielsen LM, Holm NB, Rasmussen HB, Linnet K (2014) Synthetic cannabimimetic agents metabolized by carboxylesterases. Drug Test Anal. doi:10.​1002/​dta.​1731 PubMed
27.
Zurück zum Zitat Baranczewski P, Stanczak A, Sundberg K, Svensson R, Wallin A, Jansson J, Garberg P, Postlind H (2006) Introduction to in vitro estimation of metabolic stability and drug interactions of new chemical entities in drug discovery and development. Pharmacol Rep 58:453–472PubMed Baranczewski P, Stanczak A, Sundberg K, Svensson R, Wallin A, Jansson J, Garberg P, Postlind H (2006) Introduction to in vitro estimation of metabolic stability and drug interactions of new chemical entities in drug discovery and development. Pharmacol Rep 58:453–472PubMed
28.
Zurück zum Zitat McNaney CA, Drexler DM, Hnatyshyn SY, Zvyaga TA, Knipe JO, Belcastro JV, Sanders M (2008) An automated liquid chromatography-mass spectrometry process to determine metabolic stability half-life and intrinsic clearance of drug candidates by substrate depletion. ASSAY Drug Dev Technol 6:121–129PubMedCrossRef McNaney CA, Drexler DM, Hnatyshyn SY, Zvyaga TA, Knipe JO, Belcastro JV, Sanders M (2008) An automated liquid chromatography-mass spectrometry process to determine metabolic stability half-life and intrinsic clearance of drug candidates by substrate depletion. ASSAY Drug Dev Technol 6:121–129PubMedCrossRef
29.
Zurück zum Zitat Lave T, Dupin S, Schmitt C, Valles B, Ubeaud G, Chou RC, Jaeck D, Coassolo P (1997) The use of human hepatocytes to select compounds based on their expected hepatic extraction ratios in humans. Pharm Res 14:152–155PubMedCrossRef Lave T, Dupin S, Schmitt C, Valles B, Ubeaud G, Chou RC, Jaeck D, Coassolo P (1997) The use of human hepatocytes to select compounds based on their expected hepatic extraction ratios in humans. Pharm Res 14:152–155PubMedCrossRef
30.
Zurück zum Zitat Sobolevsky T, Prasolov I, Rodchenkov G (2012) Detection of urinary metabolites of AM-2201 and UR-144, two novel synthetic cannabinoids. Drug Test Anal 4:745–753PubMedCrossRef Sobolevsky T, Prasolov I, Rodchenkov G (2012) Detection of urinary metabolites of AM-2201 and UR-144, two novel synthetic cannabinoids. Drug Test Anal 4:745–753PubMedCrossRef
31.
Zurück zum Zitat Regan SL, Maggs JL, Hammond TG, Lambert C, Williams DP, Park DK (2010) Acyl glucuronides: the good, the bad and the ugly. Biopharm Drug Dispos 31:367–395PubMedCrossRef Regan SL, Maggs JL, Hammond TG, Lambert C, Williams DP, Park DK (2010) Acyl glucuronides: the good, the bad and the ugly. Biopharm Drug Dispos 31:367–395PubMedCrossRef
32.
Zurück zum Zitat Castaneto MS, Scheidweiler KB, Gandhi A, Wohlfarth A, Klette KL, Martin TM, Huestis MA (2014) Quantitative urine confirmatory testing for synthetic cannabinoids in randomly collected urine specimens. Drug Test Anal. doi:10.1002/dta.1709 PubMedCentral Castaneto MS, Scheidweiler KB, Gandhi A, Wohlfarth A, Klette KL, Martin TM, Huestis MA (2014) Quantitative urine confirmatory testing for synthetic cannabinoids in randomly collected urine specimens. Drug Test Anal. doi:10.​1002/​dta.​1709 PubMedCentral
33.
Zurück zum Zitat Hutter M, Broecker S, Kneisel S, Auwarter V (2012) Identification of the major urinary metabolites in man of seven synthetic cannabinoids of the aminoalkylindole type present as adulterants in ‘herbal mixtures’ using LC-MS/MS techniques. J Mass Spectrom 47:54–65PubMedCrossRef Hutter M, Broecker S, Kneisel S, Auwarter V (2012) Identification of the major urinary metabolites in man of seven synthetic cannabinoids of the aminoalkylindole type present as adulterants in ‘herbal mixtures’ using LC-MS/MS techniques. J Mass Spectrom 47:54–65PubMedCrossRef
Metadaten
Titel
Identification of AB-FUBINACA metabolites in human hepatocytes and urine using high-resolution mass spectrometry
verfasst von
Marisol S. Castaneto
Ariane Wohlfarth
Shaokun Pang
Mingshe Zhu
Karl B. Scheidweiler
Robert Kronstrand
Marilyn A. Huestis
Publikationsdatum
01.07.2015
Verlag
Springer Japan
Erschienen in
Forensic Toxicology / Ausgabe 2/2015
Print ISSN: 1860-8965
Elektronische ISSN: 1860-8973
DOI
https://doi.org/10.1007/s11419-015-0275-8

Weitere Artikel der Ausgabe 2/2015

Forensic Toxicology 2/2015 Zur Ausgabe

Neu im Fachgebiet Rechtsmedizin